

Aerin Medical raises \$16.7M, adds new board members

Biotech startup <u>Aerin Medical</u> raised \$16.7 million in Series C funding on Tuesday to commercialize in select markets.

Targeted Technology Fund led the initial stage with \$6.1 million in funding, while KCK Group led the second stage with \$10.6 million. Nael Kassar of KCK Group and Peter Savas of Targeted Technology Fund will join the board of directors as part of the investment.

CEO <u>Fred Dinger</u> heads the Santa Clara-based company, which was founded in 2011 to develop devices and procedures to improve nasal breathing. Prior to Aerin Medical, Dinger served as president and CEO at ENTrigue Surgical, C2M Medical and OsteoBiologics, and has held leadership positions with A-Med Systems.

"We are extremely excited to have Targeted Technology and KCK as our lead investors. They are both experienced groups with track records of building highly innovative and successful companies,"

Dinger said in a press release. "Our non-invasive treatments are well suited to bridge the enormous gap between medical management and surgical interventions for this very large group of patients."

Clinical studies and early clinical use in over 100 patients in both the U.S. and Europe have demonstrated that Aerin's treatments are able to alleviate symptoms with minimal patient discomfort. Aerin treatment platform for the physician's office uses non-ablative radiofrequency energy to selectively target and remodel tissues contributing to nasal congestion.

The new funds will be used for building clinical evidence.

Source: http://www.bizjournals.com/sanjose/blog/techflash/2016/03/aerin-medical-raises-16-7m-adds-new-board-members.html

March 22nd 2016

